ECSP099382A - Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i - Google Patents

Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i

Info

Publication number
ECSP099382A
ECSP099382A EC2009009382A ECSP099382A ECSP099382A EC SP099382 A ECSP099382 A EC SP099382A EC 2009009382 A EC2009009382 A EC 2009009382A EC SP099382 A ECSP099382 A EC SP099382A EC SP099382 A ECSP099382 A EC SP099382A
Authority
EC
Ecuador
Prior art keywords
edg
sulfonamids
heterocyclic
antagonist activity
manufacture
Prior art date
Application number
EC2009009382A
Other languages
English (en)
Inventor
Victor Marc Kamhi
Paul Lyne
Gurmit Grewal
Edward Hennessy
Danyang Li
Vibha Oza
Jamal Carlos Saeh
Qibin Su
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38984053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099382(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP099382A publication Critical patent/ECSP099382A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos químicos de fórmula (I), (Ia) y (Ib) o sales farmacéuticamente aceptables de los mismos, los cuales poseen actividad antagonista Edg-1 y consecuentemente son útiles por su actividad anti cancerígena y así en métodos de tratamiento del cuerpo animal o humano. La invención también se refiere a procesos para la fabricación de dichos compuestos químicos, a composiciones farmacéuticas conteniéndolos y su uso en la fabricación de medicamentos para uso en la producción de efectos anti cancerígenos en animales de sangre caliente, tal como el hombre.
EC2009009382A 2006-11-10 2009-06-03 Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i ECSP099382A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86536406P 2006-11-10 2006-11-10
US89569907P 2007-03-19 2007-03-19
US94779507P 2007-07-03 2007-07-03
US95383807P 2007-08-03 2007-08-03

Publications (1)

Publication Number Publication Date
ECSP099382A true ECSP099382A (es) 2009-07-31

Family

ID=38984053

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009382A ECSP099382A (es) 2006-11-10 2009-06-03 Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i

Country Status (15)

Country Link
US (1) US20100029643A1 (es)
EP (1) EP2094670A1 (es)
JP (1) JP2010509301A (es)
KR (1) KR20090089338A (es)
AR (1) AR063625A1 (es)
AU (1) AU2007319061A1 (es)
BR (1) BRPI0718759A2 (es)
CA (1) CA2668785A1 (es)
EC (1) ECSP099382A (es)
IL (1) IL198658A0 (es)
MX (1) MX2009004906A (es)
NO (1) NO20091703L (es)
PE (1) PE20081492A1 (es)
TW (1) TW200827340A (es)
WO (1) WO2008056150A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019506A1 (en) * 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
DE102007037579B4 (de) * 2007-08-09 2012-05-16 Emc Microcollections Gmbh Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe
TW201006832A (en) * 2008-07-15 2010-02-16 Novartis Ag Organic compounds
US8288627B2 (en) * 2009-05-13 2012-10-16 Monsanto Technology Llc Plants and seeds of hybrid corn variety CH532948
KR101632318B1 (ko) * 2009-11-05 2016-06-27 재단법인 의약바이오컨버젼스연구단 벤조헤테로사이클 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 및 치료용 조성물
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
EP4095129A4 (en) * 2020-01-17 2023-10-25 Boris Slavinovich Farber BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF WITH ANTIGERIATRICAL EFFECT
CN113461611B (zh) * 2021-07-08 2023-02-28 江苏法安德医药科技有限公司 一种咪喹莫特中间体的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765348B1 (en) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1798226A4 (en) * 2004-08-04 2009-06-17 Taisho Pharmaceutical Co Ltd TRAIZOL DERIVATIVE
US8097644B2 (en) * 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
WO2007122401A1 (en) * 2006-04-21 2007-11-01 Astrazeneca Ab Imidazole derivatives for use as edg-1 antagonists

Also Published As

Publication number Publication date
WO2008056150A1 (en) 2008-05-15
JP2010509301A (ja) 2010-03-25
BRPI0718759A2 (pt) 2013-12-03
TW200827340A (en) 2008-07-01
IL198658A0 (en) 2010-02-17
AU2007319061A1 (en) 2008-05-15
EP2094670A1 (en) 2009-09-02
KR20090089338A (ko) 2009-08-21
AR063625A1 (es) 2009-02-04
PE20081492A1 (es) 2008-12-07
US20100029643A1 (en) 2010-02-04
MX2009004906A (es) 2009-07-09
NO20091703L (no) 2009-05-29
CA2668785A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
UY30282A1 (es) Compuestos quimicos
UY30094A1 (es) Compuestos químicos
UY31281A1 (es) Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
ECSP099322A (es) Compuestos químicos
UY30547A1 (es) Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones.
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
CR20130432A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
DOP2010000390A (es) Compuestos de piridina
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
ECSP10010335A (es) Pirrolo-pirimidinas y pirrolo-piridinas
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
DE602008003404D1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer
PE20151607A1 (es) Formulaciones de compuestos organicos
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
UY30585A1 (es) Derivados de isoserina como inhibidores del factor ixa de la coagulacion
MX2011013869A (es) Agentes antihelminticos y su uso.
UY30880A1 (es) 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones